Latest News and Press Releases

LAWRENCE, Mass., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is again pleased to announce full enrollment of the BTI320 Ph 2 double-blind, placebo-controlled, multicenter...

LAWRENCE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics...

LAWRENCE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel...

LAWRENCE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel...

LAWRENCE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of carbohydrate based...

LAWRENCE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel...

LAWRENCE, Mass., Aug. 24, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is pleased to announce the acceptance of the Phase IIa proof of concept study evaluating the efficacy and safety...

LAWRENCE, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (“BTI”) (OTCQB:BTHE), a BioPharmaceutical leader in the design, development and commercialization of innovative...

LAWRENCE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics...

LAWRENCE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics...